Methods for identifying risk of breast cancer and treatments thereof
First Claim
Patent Images
1. A method for identifying a subject at risk of breast cancer, which comprises detecting the presence or absence of a polymorphic variation associated with breast cancer corresponding to a position selected from the group consisting of rs5030391, rs10402760, rs710845, position 30965 of SEQ ID NO:
- 2, rs3775168, position 38865 of SEQ ID NO;
2, position 39035 of SEQ ID NO;
2, position 39046 of SEQ ID NO;
2, rs4630966, rs9827084, rs9864865, rs6804951, rs6770548, rs7949480, rs7121260, rs7128317, rs2276385, rs2276383, rs1892921, rs1541306, rs3814721, rs1892919, rs2852365, rs3750913, position 34941 in SEQ ID NO;
4, rs949325, position 35629 in SEQ ID NO;
4, rs2298456, rs1573500, rs4945411, rs10128658, rs2298457, rs3838779, rs10898814, rs7930142, rs7930544, rs7930722, rs1939247, rs1939243, rs4245463, rs4944258, rs7926751, rs1573502, rs7127865, rs1894003, rs4945430, rs1939242, rs10793016, rs4945434, rs678193, rs560777, rs676721, rs585228, rs675185, rs5792574, rs2511075, rs541022, rs1791544, rs642618, rs552966, rs607446, rs3018302, rs3018301, rs2511114, rs548961, rs579320, rs495567, rs493065, rs610004, rs610041, rs673478, rs670802, rs2511116, rs615000, rs482013, rs2511079, rs2250866, rs2508858, rs2276396, rs11278712, rs2294495, position 15761 of SEQ ID NO;
5, rs8179467, rs11591202, rs12034848, rs3831910, rs4237, rs2232982, rs12041159, rs2076343, rs1018396, rs12044452, rs2982390, rs2502980, rs6697805, rs10554242, rs3327, rs2526926, rs2526914, rs2526913, rs2526921, rs7159986, rs2332916, rs10132242, rs11627663, rs4899441, rs7148199, rs1990437, rs8004210, rs8019653, rs12232220, rs4899442, rs2332917, rs8015749, rs12437188, rs12432148, rs4378563, rs740978, rs740976, rs4903059, rs4903060, rs9635259, rs2052142, rs758913, rs747987, rs11423372, rs5809592, rs8007348, rs4899445, rs4903062, rs1990440, rs4479167, rs4606655, rs4606656, rs4489943, rs8007559, rs8006156, rs12431400, rs12431384, rs12433097, rs12433184, rs2877821, rs4569195, rs11628905, rs2191822, rs12433603, rs11448438, rs8009692, rs4265749, rs4307892, rs12431975, rs4903071, rs1860749, rs1860748, rs8010957, rs6420906, rs12434800, rs7142579, rs8010875, rs8004767, rs4899449, rs10605948, rs12437080, rs12431943, rs1054745, rs8019453, rs12431547, rs1959029, rs1959028, rs8013347, rs2235972, rs2235973, rs2235974, and rs2895908;
whereby the presence of the one or more polymorphic variations associated with breast cancer is indicative of the subject being at risk of breast cancer.
1 Assignment
0 Petitions
Accused Products
Abstract
Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.
-
Citations
47 Claims
-
1. A method for identifying a subject at risk of breast cancer, which comprises detecting the presence or absence of a polymorphic variation associated with breast cancer corresponding to a position selected from the group consisting of rs5030391, rs10402760, rs710845, position 30965 of SEQ ID NO:
- 2, rs3775168, position 38865 of SEQ ID NO;
2, position 39035 of SEQ ID NO;
2, position 39046 of SEQ ID NO;
2, rs4630966, rs9827084, rs9864865, rs6804951, rs6770548, rs7949480, rs7121260, rs7128317, rs2276385, rs2276383, rs1892921, rs1541306, rs3814721, rs1892919, rs2852365, rs3750913, position 34941 in SEQ ID NO;
4, rs949325, position 35629 in SEQ ID NO;
4, rs2298456, rs1573500, rs4945411, rs10128658, rs2298457, rs3838779, rs10898814, rs7930142, rs7930544, rs7930722, rs1939247, rs1939243, rs4245463, rs4944258, rs7926751, rs1573502, rs7127865, rs1894003, rs4945430, rs1939242, rs10793016, rs4945434, rs678193, rs560777, rs676721, rs585228, rs675185, rs5792574, rs2511075, rs541022, rs1791544, rs642618, rs552966, rs607446, rs3018302, rs3018301, rs2511114, rs548961, rs579320, rs495567, rs493065, rs610004, rs610041, rs673478, rs670802, rs2511116, rs615000, rs482013, rs2511079, rs2250866, rs2508858, rs2276396, rs11278712, rs2294495, position 15761 of SEQ ID NO;
5, rs8179467, rs11591202, rs12034848, rs3831910, rs4237, rs2232982, rs12041159, rs2076343, rs1018396, rs12044452, rs2982390, rs2502980, rs6697805, rs10554242, rs3327, rs2526926, rs2526914, rs2526913, rs2526921, rs7159986, rs2332916, rs10132242, rs11627663, rs4899441, rs7148199, rs1990437, rs8004210, rs8019653, rs12232220, rs4899442, rs2332917, rs8015749, rs12437188, rs12432148, rs4378563, rs740978, rs740976, rs4903059, rs4903060, rs9635259, rs2052142, rs758913, rs747987, rs11423372, rs5809592, rs8007348, rs4899445, rs4903062, rs1990440, rs4479167, rs4606655, rs4606656, rs4489943, rs8007559, rs8006156, rs12431400, rs12431384, rs12433097, rs12433184, rs2877821, rs4569195, rs11628905, rs2191822, rs12433603, rs11448438, rs8009692, rs4265749, rs4307892, rs12431975, rs4903071, rs1860749, rs1860748, rs8010957, rs6420906, rs12434800, rs7142579, rs8010875, rs8004767, rs4899449, rs10605948, rs12437080, rs12431943, rs1054745, rs8019453, rs12431547, rs1959029, rs1959028, rs8013347, rs2235972, rs2235973, rs2235974, and rs2895908;
whereby the presence of the one or more polymorphic variations associated with breast cancer is indicative of the subject being at risk of breast cancer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
- 2, rs3775168, position 38865 of SEQ ID NO;
-
13. A method for identifying a polymorphic variation associated with breast cancer proximal to an incident polymorphic variation associated with breast cancer, which comprises:
-
identifying a polymorphic variation proximal to the incident polymorphic variation associated with breast cancer, wherein the incident polymorphic variation is at a position corresponding to a position selected from the group consisting of rs5030391, rs10402760, rs710845, position 30965 of SEQ ID NO;
2, rs3775168, position 38865 of SEQ ID NO;
2, position 39035 of SEQ ID NO;
2, position 39046 of SEQ ID NO;
2, rs4630966, rs9827084, rs9864865, rs6804951, rs6770548, rs7949480, rs7121260, rs7128317, rs2276385, rs2276383, rs1892921, rs1541306, rs3814721, rs1892919, rs2852365, rs3750913, position 34941 in SEQ ID NO;
4, rs949325, position 35629 in SEQ ID NO;
4, rs2298456, rs1573500, rs4945411, rs10128658, rs2298457, rs3838779, rs10898814, rs7930142, rs7930544, rs7930722, rs1939247, rs1939243, rs4245463, rs4944258, rs7926751, rs1573502, rs7127865, rs1894003, rs4945430, rs1939242, rs10793016, rs4945434, rs678193, rs560777, rs676721, rs585228, rs675185, rs5792574, rs2511075, rs541022, rs1791544, rs642618, rs552966, rs607446, rs3018302, rs3018301, rs2511114, rs548961, rs579320, rs495567, rs493065, rs610004, rs610041, rs673478, rs670802, rs2511116, rs615000, rs482013, rs2511079, rs2250866, rs2508858, rs2276396, rs11278712, rs2294495, position 15761 of SEQ ID NO;
5, rs8179467, rs11591202, rs12034848, rs3831910, rs4237, rs2232982, rs12041159, rs2076343, rs018396, rs12044452, rs2982390, rs2502980, rs6697805, rs10554242, rs3327, rs2526926, rs2526914, rs2526913, rs2526921, rs7159986, rs2332916, rs0132242, rs11627663, rs4899441, rs7148199, rs1990437, rs8004210, rs8019653, rs12232220, rs4899442, rs2332917, rs8015749, rs12437188, rs12432148, rs4378563, rs740978, rs740976, rs4903059, rs4903060, rs9635259, rs2052142, rs758913, rs747987, rs11423372, rs5809592, rs8007348, rs4899445, rs4903062, rs1990440, rs4479167, rs4606655, rs4606656, rs4489943, rs8007559, rs8006156, rs12431400, rs12431384, rs12433097, rs12433184, rs2877821, rs4569195, rs11628905, rs2191822, rs12433603, rs11448438, rs8009692, rs4265749, rs4307892, rs12431975, rs4903071, rs1860749, rs1860748, rs8010957, rs6420906, rs12434800, rs7142579, rs8010875, rs8004767, rs4899449, rs10605948, rs12437080, rs12431943, rs1054745, rs8019453, rs12431547, rs1959029, rs1959028, rs8013347, rs2235972, rs2235973, rs2235974, and rs2895908; and
determining the presence or absence of an association of the proximal polymorphic variant with breast cancer. - View Dependent Claims (14, 15, 16, 17)
-
-
18. An isolated nucleic acid which comprises one or more polymorphic variations corresponding to a variation selected from the group consisting of a thymine at position 45003 of SEQ ID NO:
- 1, an adenine at position 47504 of SEQ ID NO;
1, an adenine at position 30965 of SEQ ID NO;
2, a cytosine at position 38865 of SEQ ID NO;
2, a thymine at position 39035 of SEQ ID NO;
2, a cytosine at position 39046 of SEQ ID NO;
2, a cytosine at position 34941 in SEQ ID NO;
4, a guanine at position 35629 in SEQ ID NO;
4 and an adenine at position 15761 of SEQ ID NO;
5. - View Dependent Claims (19, 20)
- 1, an adenine at position 47504 of SEQ ID NO;
-
21. A method of genotyping a nucleic acid which comprises determining the nucleotide at one or more positions corresponding to a position selected from the group consisting of position 45003 of SEQ ID NO:
- 1, position 47504 of SEQ ID NO;
1, position 30965 of SEQ ID NO;
2, position 38865 of SEQ ID NO;
2, position 39035 of SEQ ID NO;
2, position 39046 of SEQ ID NO;
2, position 34941 in SEQ ID NO;
4, position 35629 in SEQ ID NO;
4 and position 15761 of SEQ ID NO;
5 in a nucleic acid.
- 1, position 47504 of SEQ ID NO;
-
22. A method for identifying a candidate molecule that modulates cell proliferation, which comprises:
-
(a) introducing a test molecule to a system which comprises a nucleic acid comprising a nucleotide sequence selected from the group consisting of;
(i) a nucleotide sequence in SEQ ID NO;
1-17;
(ii) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO;
1-17;
(iii) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO;
1-17;
(iv) a fragment of a nucleotide sequence of (i), (ii), or (iii);
wherein the nucleotide sequence comprises a polymorphic variation associated with an increased risk of breast cancer corresponding to a position selected from the group consisting of rs5030391, rs10402760, rs710845, position 30965 of SEQ ID NO;
2, rs3775168, position 38865 of SEQ ID NO;
2, position 39035 of SEQ ID NO;
2, position 39046 of SEQ ID NO;
2, rs4630966, rs9827084, rs9864865, rs6804951, rs6770548, rs7949480, rs7121260, rs7128317, rs2276385, rs2276383, rs1892921, rs1541306, rs3814721, rs1892919, rs2852365, rs3750913, position 34941 in SEQ ID NO;
4, rs949325, position 35629 in SEQ ID NO;
4, rs2298456, rs1573500, rs4945411, rs10128658, rs2298457, rs3838779, rs10898814, rs7930142, rs7930544, rs7930722, rs1939247, rs1939243, rs4245463, rs4944258, rs7926751, rs1573502, rs7127865, rs1894003, rs4945430, rs1939242, rs10793016, rs4945434, rs678193, rs560777, rs676721, rs585228, rs675185, rs5792574, rs2511075, rs541022, rs1791544, rs642618, rs552966, rs607446, rs3018302, rs3018301, rs2511114, rs548961, rs579320, rs495567, rs493065, rs610004, rs610041, rs673478, rs670802, rs2511116, rs615000, rs482013, rs2511079, rs2250866, rs2508858, rs2276396, rs11278712, rs2294495, position 15761 of SEQ ID NO;
5, rs8179467, rs11591202, rs12034848, rs3831910, rs4237, rs2232982, rs12041159, rs2076343, rs1018396, rs12044452, rs2982390, rs2502980, rs6697805, rs10554242, rs3327, rs2526926, rs2526914, rs2526913, rs2526921, rs7159986, rs2332916, rs10132242, rs11627663, rs4899441, rs7148199, rs1990437, rs8004210, rs8019653, rs12232220, rs4899442, rs2332917, rs8015749, rs12437188, rs12432148, rs4378563, rs740978, rs740976, rs4903059, rs4903060, rs9635259, rs2052142, rs758913, rs747987, rs11423372, rs5809592, rs8007348, rs4899445, rs4903062, rs1990440, rs4479167, rs4606655, rs4606656, rs4489943, rs8007559, rs8006156, rs12431400, rs12431384, rs12433097, rs12433184, rs2877821, rs4569195, rs11628905, rs2191822, rs12433603, rs11448438, rs8009692, rs4265749, rs4307892, rs12431975, rs4903071, rs1860749, rs1860748, rs8010957, rs6420906, rs12434800, rs7142579, rs8010875, rs8004767, rs4899449, rs10605948, rs12437080, rs12431943, rs1054745, rs8019453, rs12431547, rs1959029, rs1959028, rs8013347, rs2235972, rs2235973, rs2235974, and rs2895908;
orintroducing a test molecule to a system which comprises a protein encoded by a nucleotide sequence of (i), (ii), (iii), or (iv) and comprises a polymorphic variation associated with an increased risk of breast cancer; and
(b) determining the presence or absence of an interaction between the test molecule and the nucleic acid or protein, whereby the presence of an interaction between the test molecule and the nucleic acid or protein identifies the test molecule as a candidate molecule that modulates cell proliferation. - View Dependent Claims (23, 24, 25)
-
-
26. A method for identifying a candidate therapeutic for treating breast cancer, which comprises:
-
(a) introducing a test molecule to a system which comprises a nucleic acid comprising a nucleotide sequence selected from the group consisting of;
(i) a nucleotide sequence in SEQ ID NO;
1-17;
(ii) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO;
1-17;
(iii) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO;
1-17;
(iv) a fragment of a nucleotide sequence of (i), (ii), or (iii);
wherein the nucleotide sequence comprises a polymorphic variation associated with an increased risk of breast cancer corresponding to a position selected from the group consisting of rs5030391, rs10402760, rs710845, position 30965 of SEQ ID NO;
2, rs3775168, position 38865 of SEQ ID NO;
2, position 39035 of SEQ ID NO;
2, position 39046 of SEQ ID NO;
2, rs4630966, rs9827084, rs9864865, rs6804951, rs6770548, rs7949480, rs7121260, rs7128317, rs2276385, rs2276383, rs1892921, rs1541306, rs3814721, rs1892919, rs2852365, rs3750913, position 34941 in SEQ ID NO;
4, rs949325, position 35629 in SEQ ID NO;
4, rs2298456, rs1573500, rs4945411, rs10128658, rs2298457, rs3838779, rs10898814, rs7930142, rs7930544, rs7930722, rs1939247, rs1939243, rs4245463, rs4944258, rs7926751, rs1573502, rs7127865, rs1894003, rs4945430, rs1939242, rs10793016, rs4945434, rs678193, rs560777, rs676721, rs585228, rs675185, rs5792574, rs2511075, rs541022, rs1791544, rs642618, rs552966, rs607446, rs3018302, rs3018301, rs2511114, rs548961, rs579320, rs495567, rs493065, rs610004, rs610041, rs673478, rs670802, rs2511116, rs615000, rs482013, rs2511079, rs2250866, rs2508858, rs2276396, rs11278712, rs2294495, position 15761 of SEQ ID NO;
5, rs8179467, rs11591202, rs12034848, rs3831910, rs4237, rs2232982, rs12041159, rs2076343, rs1018396, rs12044452, rs2982390, rs2502980, rs6697805, rs10554242, rs3327, rs2526926, rs2526914, rs2526913, rs2526921, rs7159986, rs2332916, rs10132242, rs11627663, rs4899441, rs7148199, rs1990437, rs8004210, rs8019653, rs12232220, rs4899442, rs2332917, rs8015749, rs12437188, rs12432148, rs4378563, rs740978, rs740976, rs4903059, rs4903060, rs9635259, rs2052142, rs758913, rs747987, rs11423372, rs5809592, rs8007348, rs4899445, rs4903062, rs1990440, rs4479167, rs4606655, rs4606656, rs4489943, rs8007559, rs8006156, rs12431400, rs12431384, rs12433097, rs12433184, rs2877821, rs4569195, rs11628905, rs2191822, rs12433603, rs11448438, rs8009692, rs4265749, rs4307892, rs12431975, rs4903071, rs1860749, rs1860748, rs8010957, rs6420906, rs12434800, rs7142579, rs8010875, rs8004767, rs4899449, rs10605948, rs12437080, rs12431943, rs1054745, rs8019453, rs12431547, rs1959029, rs1959028, rs8013347, rs2235972, rs2235973, rs2235974, and rs2895908;
orintroducing a test molecule to a system which comprises a protein encoded by a nucleotide sequence of (i), (ii), (iii), or (iv) and comprises a polymorphic variation associated with an increased risk of breat cancer; and
(b) determining the presence or absence of an interaction between the test molecule and the nucleic acid or protein, whereby the presence of an interaction between the test molecule and the nucleic acid or protein identifies the test molecule as a candidate therapeutic for treating breast cancer. - View Dependent Claims (27)
-
-
28. A method for treating breast cancer in a subject, which comprises contacting one or more cells of a subject in need thereof with a nucleic acid, wherein the nucleic acid comprises a nucleotide sequence selected from the group consisting of:
-
(a) a nucleotide sequence in SEQ ID NO;
1-17;
(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO;
1-17;
(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO;
1-17;
(d) a fragment of a nucleotide sequence of (a), (b), or (c); and
(e) a nucleotide sequence complementary to the nucleotide sequences of (a), (b), (c), or (d);
wherein the nucleotide sequence comprises a polymorphic variation associated with an increased risk of breast cancer corresponding to a position selected from the group consisting of rs5030391, rs10402760, rs710845, position 30965 of SEQ ID NO;
2, rs3775168, position 38865 of SEQ ID NO;
2, position 39035 of SEQ ID NO;
2, position 39046 of SEQ ID NO;
2, rs4630966, rs9827084, rs9864865, rs6804951, rs6770548, rs7949480, rs7121260, rs7128317, rs2276385, rs2276383, rs1892921, rs1541306, rs3814721, rs1892919, rs2852365, rs3750913, position 34941 in SEQ ID NO;
4, rs949325, position 35629 in SEQ ID NO;
4, rs2298456, rs1573500, rs4945411, rs10128658, rs2298457, rs3838779, rs10898814, rs7930142, rs7930544, rs7930722, rs1939247, rs1939243, rs4245463, rs4944258, rs7926751, rs1573502, rs7127865, rs1894003, rs4945430, rs1939242, rs10793016, rs4945434, rs678193, rs560777, rs676721, rs585228, rs675185, rs5792574, rs2511075, rs541022, rs1791544, rs642618, rs552966, rs607446, rs3018302, rs3018301, rs2511114, rs548961, rs579320, rs495567, rs493065, rs610004, rs610041, rs673478, rs670802, rs2511116, rs615000, rs482013, rs2511079, rs2250866, rs2508858, rs2276396, rs11278712, rs2294495, position 15761 of SEQ ID NO;
5, rs8179467, rs11591202, rs12034848, rs3831910, rs4237, rs2232982, rs12041159, rs2076343, rs1018396, rs12044452, rs2982390, rs2502980, rs6697805, rs10554242, rs3327, rs2526926, rs2526914, rs2526913, rs2526921, rs7159986, rs2332916, rs0132242, rs11627663, rs4899441, rs7148199, rs1990437, rs8004210, rs8019653, rs12232220, rs4899442, rs2332917, rs8015749, rs12437188, rs12432148, rs4378563, rs740978, rs740976, rs4903059, rs4903060, rs9635259, rs2052142, rs758913, rs747987, rs11423372, rs5809592, rs8007348, rs4899445, rs4903062, rs1990440, rs4479167, rs4606655, rs4606656, rs4489943, rs8007559, rs8006156, rs12431400, rs12431384, rs12433097, rs12433184, rs2877821, rs4569195, rs11628905, rs2191822, rs12433603, rs11448438, rs8009692, rs4265749, rs4307892, rs12431975, rs4903071, rs1860749, rs1860748, rs8010957, rs6420906, rs12434800, rs7142579, rs8010875, rs8004767, rs4899449, rs10605948, rs12437080, rs12431943, rs1054745, rs8019453, rs12431547, rs1959029, rs1959028, rs8013347, rs2235972, rs2235973, rs2235974, and rs2895908;
whereby contacting the one or more cells of the subject with the nucleic acid treats breast cancer in the subject. - View Dependent Claims (29, 30, 31)
-
-
32. A method for treating breast cancer in a subject, which comprises:
-
detecting the presence or absence of one or more polymorphic variations associated with breast cancer in a nucleic acid sample from a subject, wherein the one or more polymorphic variations are detected at a position corresponding to a position selected from the group consisting of rs5030391, rs10402760, rs710845, position 30965 of SEQ ID NO;
2, rs3775168, position 38865 of SEQ ID NO;
2, position 39035 of SEQ ID NO;
2, position 39046 of SEQ ID NO;
2, rs4630966, rs9827084, rs9864865, rs6804951, rs6770548, rs7949480, rs7121260, rs7128317, rs2276385, rs2276383, rs1892921, rs1541306, rs3814721, rs1892919, rs2852365, rs3750913, position 34941 in SEQ ID NO;
4, rs949325, position 35629 in SEQ ID NO;
4, rs2298456, rs1573500, rs4945411, rs10128658, rs2298457, rs3838779, rs10898814, rs7930142, rs7930544, rs7930722, rs1939247, rs1939243, rs4245463, rs4944258, rs7926751, rs1573502, rs7127865, rs1894003, rs4945430, rs1939242, rs10793016, rs4945434, rs678193, rs560777, rs676721, rs585228, rs675185, rs5792574, rs2511075, rs541022, rs1791544, rs642618, rs552966, rs607446, rs3018302, rs3018301, rs2511114, rs548961, rs579320, rs495567, rs493065, rs610004, rs610041, rs673478, rs670802, rs2511116, rs615000, rs482013, rs2511079, rs2250866, rs2508858, rs2276396, rs11278712, rs2294495, position 15761 of SEQ ID NO;
5, rs8179467, rs11591202, rs12034848, rs3831910, rs4237, rs2232982, rs12041159, rs2076343, rs1018396, rs12044452, rs2982390, rs2502980, rs6697805, rs10554242, rs3327, rs2526926, rs2526914, rs2526913, rs2526921, rs7159986, rs2332916, rs10132242, rs11627663, rs4899441, rs7148199, rs1990437, rs8004210, rs8019653, rs12232220, rs4899442, rs2332917, rs8015749, rs12437188, rs12432148, rs4378563, rs740978, rs740976, rs4903059, rs4903060, rs9635259, rs2052142, rs758913, rs747987, rs11423372, rs5809592, rs8007348, rs4899445, rs4903062, rs1990440, rs4479167, rs4606655, rs4606656, rs4489943, rs8007559, rs8006156, rs12431400, rs12431384, rs12433097, rs12433184, rs2877821, rs4569195, rs11628905, rs2191822, rs12433603, rs11448438, rs8009692, rs4265749, rs4307892, rs12431975, rs4903071, rs1860749, rs1860748, rs8010957, rs6420906, rs12434800, rs7142579, rs8010875, rs8004767, rs4899449, rs10605948, rs12437080, rs12431943, rs1054745, rs8019453, rs12431547, rs1959029, rs1959028, rs8013347, rs2235972, rs2235973, rs2235974, and rs2895908; and
administering a breast cancer treatment to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample. - View Dependent Claims (33, 34, 35, 36, 37, 38, 39, 40)
-
-
41. A method for detecting or preventing breast cancer in a subject, which comprises:
-
detecting the presence or absence of one or more polymorphic variations associated with breast cancer in a nucleic acid sample from a subject, wherein the polymorphic variation is detected at a position corresponding to a position selected from the group consisting of rs5030391, rs10402760, rs710845, position 30965 of SEQ ID NO;
2, rs3775168, position 38865 of SEQ ID NO;
position 39035 of SEQ ID NO;
2, position 39046 of SEQ ID NO;
2, rs4630966, rs9827084, rs9864865, rs6804951, rs6770548, rs7949480, rs7121260, rs7128317, rs2276385, rs2276383, rs1892921, rs1541306, rs3814721, rs1892919, rs2852365, rs3750913, position 34941 in SEQ ID NO;
rs949325, position 35629 in SEQ ID NO;
4, rs2298456, rs1573500, rs4945411, rs10128658, rs2298457, rs3838779, rs10898814, rs7930142, rs7930544, rs7930722, rs1939247, rs1939243, rs4245463, rs4944258, rs7926751, rs1573502, rs7127865, rs1894003, rs4945430, rs1939242, rs10793016, rs4945434, rs678193, rs560777, rs676721, rs585228, rs675185, rs5792574, rs2511075, rs541022, rs1791544, rs642618, rs552966, rs607446, rs3018302, rs3018301, rs2511114, rs548961, rs579320, rs495567, rs493065, rs610004, rs610041, rs673478, rs670802, rs2511116, rs615000, rs482013, rs2511079, rs2250866, rs2508858, rs2276396, rs11278712, rs2294495, position 15761 of SEQ ID NO;
5, rs8179467, rs11591202, rs12034848, rs3831910, rs4237, rs2232982, rs12041159, rs2076343, rs018396, rs12044452, rs2982390, rs2502980, rs6697805, rs10554242, rs3327, rs2526926, rs2526914, rs2526913, rs2526921, rs7159986, rs2332916, rs0132242, rs11627663, rs4899441, rs7148199, rs1990437, rs8004210, rs8019653, rs12232220, rs4899442, rs2332917, rs8015749, rs12437188, rs12432148, rs4378563, rs740978, rs740976, rs4903059, rs4903060, rs9635259, rs2052142, rs758913, rs747987, rs11423372, rs5809592, rs8007348, rs4899445, rs4903062, rs1990440, rs4479167, rs4606655, rs4606656, rs4489943, rs8007559, rs8006156, rs12431400, rs12431384, rs12433097, rs12433184, rs2877821, rs4569195, rs11628905, rs2191822, rs12433603, rs11448438, rs8009692, rs4265749, rs4307892, rs12431975, rs4903071, rs1860749, rs1860748, rs8010957, rs6420906, rs12434800, rs7142579, rs8010875, rs8004767, rs4899449, rs10605948, rs12437080, rs12431943, rs1054745, rs8019453, rs12431547, rs1959029, rs1959028, rs8013347, rs2235972, rs2235973, rs2235974, and rs2895908; and
administering a breast cancer prevention procedure or detection procedure to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample. - View Dependent Claims (42, 43, 44)
-
-
45. A composition comprising a breast cancer cell and an antibody that specifically binds to a protein, polypeptide or peptide encoded by a nucleotide sequence identical to or 90% or more identical to a nucleotide sequence in SEQ ID NO:
- 1-17, wherein the protein, polypeptide or peptide comprises a leucine corresponding to the amino acid at position 359 in SEQ ID NO;
23, a leucine corresponding to the amino acid at position 378 in SEQ ID NO;
23, an alanine corresponding to the amino acid at position 857 in SEQ ID NO;
23, an alanine corresponding to the amino acid at position 902 in SEQ ID NO;
23, a proline corresponding to the amino acid at position 352 in SEQ ID NO;
20, an alanine corresponding to the amino acid at position 348 in SEQ ID NO;
20 or a glycine corresponding to the amino acid at position 794 in SEQ ID NO;
24.
- 1-17, wherein the protein, polypeptide or peptide comprises a leucine corresponding to the amino acid at position 359 in SEQ ID NO;
-
46. A composition comprising a breast cancer cell and a RNA, DNA, PNA or ribozyme molecule comprising a nucleotide sequence identical to or 90% or more identical to a portion of a nucleotide sequence in SEQ ID NO:
- 1-17, or a complementary sequence thereof, wherein the nucleotide sequence comprises a polymorphic variation associated with an increased risk of breast cancer corresponding to a position selected from the group consisting of group consisting of rs5030391, rs10402760, rs710845, position 30965 of SEQ ID NO;
2, rs3775168, position 38865 of SEQ ID NO;
2, position 39035 of SEQ ID NO;
2, position 39046 of SEQ ID NO;
2, rs4630966, rs9827084, rs9864865, rs6804951, rs6770548, rs7949480, rs7121260, rs7128317, rs2276385, rs2276383, rs1892921, rs1541306, rs3814721, rs1892919, rs2852365, rs3750913, position 34941 in SEQ ID NO;
4, rs949325, position 35629 in SEQ ID NO;
4, rs2298456, rs1573500, rs4945411, rs10128658, rs2298457, rs3838779, rs10898814, rs7930142, rs7930544, rs7930722, rs1939247, rs1939243, rs4245463, rs4944258, rs7926751, rs1573502, rs7127865, rs1894003, rs4945430, rs1939242, rs10793016, rs4945434, rs678193, rs560777, rs676721, rs585228, rs675185, rs5792574, rs2511075, rs541022, rs1791544, rs642618, rs552966, rs607446, rs3018302, rs3018301, rs2511114, rs548961, rs579320, rs495567, rs493065, rs610004, rs610041, rs673478, rs670802, rs2511116, rs615000, rs482013, rs2511079, rs2250866, rs2508858, rs2276396, rs11278712, rs2294495, position 15761 of SEQ ID NO;
5, rs8179467, rs11591202, rs12034848, rs3831910, rs4237, rs2232982, rs12041159, rs2076343, rs1018396, rs12044452, rs2982390, rs2502980, rs6697805, rs10554242, rs3327, rs2526926, rs2526914, rs2526913, rs2526921, rs7159986, rs2332916, rs10132242, rs11627663, rs4899441, rs7148199, rs1990437, rs8004210, rs8019653, rs12232220, rs4899442, rs2332917, rs8015749, rs12437188, rs12432148, rs4378563, rs740978, rs740976, rs4903059, rs4903060, rs9635259, rs2052142, rs758913, rs747987, rs11423372, rs5809592, rs8007348, rs4899445, rs4903062, rs1990440, rs4479167, rs4606655, rs4606656, rs4489943, rs8007559, rs8006156, rs12431400, rs12431384, rs12433097, rs12433184, rs2877821, rs4569195, rs11628905, rs2191822, rs12433603, rs11448438, rs8009692, rs4265749, rs4307892, rs12431975, rs4903071, rs1860749, rs1860748, rs8010957, rs6420906, rs12434800, rs7142579, rs8010875, rs8004767, rs4899449, rs10605948, rs12437080, rs12431943, rs1054745, rs8019453, rs12431547, rs1959029, rs1959028, rs8013347, rs2235972, rs2235973, rs2235974, and rs2895908. - View Dependent Claims (47)
- 1-17, or a complementary sequence thereof, wherein the nucleotide sequence comprises a polymorphic variation associated with an increased risk of breast cancer corresponding to a position selected from the group consisting of group consisting of rs5030391, rs10402760, rs710845, position 30965 of SEQ ID NO;
Specification